Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Cajal Neuroscience launches with $96 million for neurodegeneration

by Gina Vitale
December 1, 2022 | A version of this story appeared in Volume 100, Issue 43

 

Cajal Neuroscience has launched with $96 million in series A financing to find targets and therapeutics for neurodegeneration. The Seattle-based company says it aims to uncover the mechanisms behind neurogenerative disease and that it is validating targets implicated in conditions like Parkinson’s and Alzheimer’s. Cajal gets its name from Santiago Ramón y Cajal, a Nobel-winning Spanish physician who studied the nervous system.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.